HAVN Life Sciences Inc.
HAVLF · OTC
1/31/2023 | 10/31/2022 | 7/31/2022 | 4/30/2022 | |
|---|---|---|---|---|
| Revenue | -$12 | $315 | $68 | $216 |
| % Growth | -103.8% | 363.5% | -68.6% | – |
| Cost of Goods Sold | $71 | $113 | $46 | $148 |
| Gross Profit | -$83 | $202 | $22 | $68 |
| % Margin | 690.9% | 64.1% | 32.4% | 31.5% |
| R&D Expenses | $56 | $169 | $144 | $131 |
| G&A Expenses | $589 | $748 | $745 | $1,664 |
| SG&A Expenses | $611 | $770 | $784 | $1,460 |
| Sales & Mktg Exp. | $21 | $22 | $39 | -$204 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $667 | $940 | $974 | $1,756 |
| Operating Income | -$750 | -$1,251 | -$952 | $1,195 |
| % Margin | 6,222.1% | -397.6% | -1,401.4% | 552.4% |
| Other Income/Exp. Net | $59 | -$1,227 | -$2,754 | -$12,562 |
| Pre-Tax Income | -$692 | -$2,479 | -$3,903 | -$11,367 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$692 | -$2,479 | -$3,903 | -$11,367 |
| % Margin | 5,734.1% | -787.5% | -5,747.4% | -5,253.1% |
| EPS | -0.071 | -0.41 | -27.05 | -2.38 |
| % Growth | 82.6% | 98.5% | -1,036.6% | – |
| EPS Diluted | -0.071 | -0.41 | -27.05 | -2.38 |
| Weighted Avg Shares Out | 9,714 | 6,075 | 144 | 4,776 |
| Weighted Avg Shares Out Dil | 9,714 | 6,075 | 144 | 4,776 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $14 | $15 |
| Depreciation & Amortization | $0 | $0 | $46 | $165 |
| EBITDA | -$691 | -$603 | -$906 | -$11,186 |
| % Margin | 5,733.3% | -191.7% | -1,334.3% | -5,169.6% |